Tamoxifen inhibits transforming growth factor-α gene expression in human breast carcinoma samples treated with triiodothyronine

Conde, Sandro José; Luvizotto, Renata de Azevedo Melo; Síbio, Maria Teresa De; Katayama, Maria Lúcia Hirata; Brentani, Maria Mitzi; Nogueira, Célia Regina

doi:10.1007/bf03345650

Cited by 19 publications

(17 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In previous work, we demonstrated that TGFA expression increases after treatment with triiodothyronine (T 3 ) in MCF7 cells the same effect was observed in primary cultures [18,19].…”

Section: Introductionmentioning

confidence: 56%

Triiodothyronine (T3) induces HIF1A and TGFA expression in MCF7 cells by activating PI3K

et al. 2016

View full text Add to dashboard Cite

High expression levels of hypoxia inducing factor 1 alpha are related to mammary carcinogenesis. In previous studies, we demonstrated that expression of transforming growth factor alpha increases upon treatment with triiodothyronine, but this expression does not occur in cellular models that do not express the estrogen receptor, or when cells are co-treated with the anti-estrogen, tamoxifen. The aim of this study was to determine the effect of the hormone triiodothyronine on the expression of the genes HIF1A and TGFA in the breast cancer cell line MCF7. The cell line was subjected to treatment with triiodothyronine at the supraphysiological dose of 10(-8)M for 10min, 30min, 1h, and 4h in the presence or absence of actinomycin D, the gene expression inhibitor, cycloheximide, the protein synthesis inhibitor, and LY294002, the phosphoinositide 3 kinase inhibitor. HIF1A and TGFA mRNA expression was analyzed by reverse transcription polymerase chain reaction. For data analysis, we used analysis of variance complemented by Tukey test and an adopted minimum of 5% significance. We found that HIF1A and TGFA expression increased in the presence of triiodothyronine at all times studied. HIF1A expression decreased in triiodothyronine-treated cells when gene transcription was also inhibited; however, TGFA expression decreased after 10 and 30min of treatment even when transcription was not inhibited. We found that activation of PI3K was necessary for triiodothyronine to modulate HIF1A and TGFA expression.

show abstract

“…In previous work, we demonstrated that TGFA expression increases after treatment with triiodothyronine (T 3 ) in MCF7 cells the same effect was observed in primary cultures [18,19].…”

Section: Introductionmentioning

confidence: 56%

Triiodothyronine (T3) induces HIF1A and TGFA expression in MCF7 cells by activating PI3K

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Usando culturas primárias de CaM sob tratamen to com E2 e T3, identificamos uma expressão aumen tada de genes relacionados à evolução do ciclo celu lar (CLND1) e de aumento da atividade proliferativa (TGFA) em ambos os tratamentos (40). Em outro gru po de pacientes, as culturas primárias mostraram tam bém diminuição de TGFB1, relacionado a um efeito antiproliferativo, em ambos os tratamentos (39), repe tindo os resultados observados em linhagens MCF7, mas que não foram reproduzidos quando as linhagens não apresentavam o ER como a MDAMD231 (18).…”

Section: Resultsunclassified

“…Porém, quando o tratamento com TAM associado ao T3 foi empregado nas culturas primárias, observouse aumento da expressão de TGFA e diminuição da expressão de TGFB1, diferentemente das linhagens celulares (18,39,40).…”

Section: Resultsunclassified

Perfil dos hormônios da tireoide em pacientes com câncer de mama em estado de menopausa

Conde

Luvizotto

Síbio

et al. 2012

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

ReSUMOObjetivo: Verificar o perfil dos hormônios tireóideos (HTs) em pacientes pós-menopausa portadoras de carcinoma de mama (CaM). Sujeitos e métodos: Participaram 12 pacientes com CaM em estádio I ou II sem intervenções que pudessem interferir na progressão tumoral e um grupo controle com 18 pacientes em pós-menopausa sem CaM. Foram dosados os níveis séricos de anticorpo antitiroperoxidase (TPOAB), hormônio estimulante da tireoide (TSH), tiroxina livre (T4L), estradiol (E2), hormônio folículo estimulante (FSH) e hormônio luteinizante (LH) antes e após a cirurgia, e realizada a imunoistoquímica dos receptores de estrógeno (ER) e progesterona (PR). Resultados: Quatro pacientes com CaM apresentaram alterações do perfil hormonal tireoidiano: dois hipertireoidismo, um hipotireoidismo e positividade TPO-AB, todas com ER e PR positivos. Os níveis de TSH dessas pacientes não foram diferentes dos níveis encontrados no grupo controle (1,89 ± 1,56 vs. 2,86 ± 3,12 mUI/mL), porém os níveis de T4L nas pacientes com CaM foram estatisticamente maiores que o controle (1,83 ± 0,57 vs. 1,10 ± 0,20 ng/dL). Conclusão: Esses resultados reforçam a necessidade de avaliação do status tireoidiano em pacientes com CaM, uma vez que, na ausência de E2, mudanças clínicas nos HTs podem atuar em vias controladas pelo E2. Arq Bras Endocrinol Metab. 2012;56(4):238-43 Descritores Hormônios tireóideos; neoplasias da mama; hipertireoidismo; pós-menopausa ABSTRACT Objective: The aim of this study was to determine thyroid hormone (TH) profile in postmenopausal patients with breast cancer (BC). Subjects and methods: 12 CaM patients stages I or II, without interventions that could interfere with tumor progression were selected, as well as and a control group with 18 postmenopausal women without CaM. We measured serum anti--thyroperoxidase antibody (TPOAB), thyroid-stimulating hormone (TSH), free thyroxine (T4L), estradiol (E2), follicle-stimulating hormone (FSH), and luteinizing hormone (LH), before and after surgery, besides immunohistochemistry for estrogen (ER) and progesterone (PR) receptors. Results: Four patients with CaM showed changes in thyroid hormone profile: two had hyperthyroidism, one hypothyroidism, and one was positive for TPO-AB. All of them positive for ER and PR. TSH levels in breast cancer patients were not different from levels found in the control group (1.89 ± 1.56 vs. 2.86 ± 3.12 mIU/mL), but the levels of T4L in patients with CaM were statistically higher than those of the control group (1.83 ± 0.57 vs. 1.10 ± 0.20 ng/dL). Conclusion: These results reinforce the need for assessment of thyroid status in CaM patients, since in the absence of E2, changes in clinical HTs can act in E2-controlled processes. Arq Bras Endocrinol Metab. 2012;56(4):238-43

show abstract

“…The results showed that the modified oncolytic adenovirus can infect and replicate in breast cancer tissue slices, suggesting the great potential of this model for evaluating the potential of oncolytic adenovirus constructs (Pennington et al 2010). This list is not exhaustive and the literature shows that a lot of results were obtained by the slice culturing method, more particularly on the study of drugs effects like tamoxifen or paclitaxel (Conde et al 2008;Sonnenberg et al 2008;Rajendran et al 2011). Although used since the late 70's, the slice technique evolved over time and was adapted to technological innovations.…”

Section: Improving Representativeness Of the Model: Direct Culture Ofmentioning

confidence: 99%

In Vitro Breast Cancer Models as Useful Tools in Therapeutics?

Bana¹,

Bagrel²

2011

Breast Cancer - Focusing Tumor Microenvironment, Stem Cells and Metastasis

View full text Add to dashboard Cite

Tamoxifen inhibits transforming growth factor-α gene expression in human breast carcinoma samples treated with triiodothyronine

Cited by 19 publications

References 33 publications

Triiodothyronine (T3) induces HIF1A and TGFA expression in MCF7 cells by activating PI3K

Triiodothyronine (T3) induces HIF1A and TGFA expression in MCF7 cells by activating PI3K

Perfil dos hormônios da tireoide em pacientes com câncer de mama em estado de menopausa

In Vitro Breast Cancer Models as Useful Tools in Therapeutics?

Contact Info

Product

Resources

About